Information Provided By: 
Fly News Breaks for August 30, 2018
RARE
Aug 30, 2018 | 07:18 EDT
Wedbush analyst David Nierengarten raised his price target for Ultragenyx to $90 from $80, while reiterating an Outperform rating on the shares. With FDA appearing to be favorably disposed toward early approval of UX007 in long-chain fatty acid oxidation disorders, the analyst is advancing his launch time to late 2019 from first half of 2021 and reducing discount rate to 20% from 25%.
News For RARE From the Last 2 Days
